FDA Approves Higher Dose SMA Treatment for Faster Results

Families fighting spinal muscular atrophy just got stronger weapons in their corner.

The FDA approved a high dose version of SPINRAZA this week, a treatment that helps children with SMA gain crucial motor function and strength. The new regimen delivers higher concentrations of the drug and works faster than the original version that's been changing lives for nearly a decade.

The approval matters most for the tiniest patients. In clinical trials, babies who received the high dose treatment showed dramatic improvements in motor function, scoring 26 points higher on movement tests than untreated infants. That's the difference between struggling to lift a head and being able to sit up, between weak swallows and safer feeding.

SMA attacks the nerve cells that control voluntary muscles, making it hard for children to move, eat, and even breathe. Before SPINRAZA arrived in 2017, families had no treatment options. Now they have two dosing choices, with the high dose offering an accelerated path to results.

The new regimen starts with two high dose injections given two weeks apart, then switches to maintenance doses every four months. Patients already on the standard dose can transition to the higher strength while keeping their regular schedule. The treatment will reach pharmacies within weeks.

Dr. Richard Finkel, who leads experimental treatments at St. Jude Children's Research Hospital, called the approval an important step forward. The high dose showed meaningful clinical benefits while maintaining the safety profile doctors have observed over ten years of use with the original version.

The Ripple Effect spreads beyond individual families. More than 10,000 patients worldwide have received SPINRAZA treatment since its initial approval. Each dosing improvement helps the entire community, giving newly diagnosed families hope and existing patients new options. The treatment is already approved in the European Union, Switzerland, and Japan, with more countries reviewing it now.

Kenneth Hobby, president of Cure SMA, emphasized that Biogen has remained a committed partner in advancing research that improves daily life for people living with SMA. The company spent years studying how to optimize the dose, listening to community needs and building on clinical evidence.

Another generation of children will grow up with possibilities their parents never imagined possible.